Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{161663,
        author = {Gangu Sreelatha and N. Sai Lokesh and K. Sanihitha},
        title = {A Review on Various Analytical and Biological Methods for the Determination of Tepotinib},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {10},
        number = {5},
        pages = {312-317},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=161663},
        abstract = {Tepotinib is a MET tyrosine kinase inhibitor used to treat solid tumors that overexpress MET. There were several phases of clinical trials, and only a few analytical methods for Tepotinib were established using RP-HPLC technology. Chromatography makes use of the stationary phase. Ascentis 150 mm x 4.6 mm x 2.7 m, mobile phase Acetonitrile: 0.1% OPA in a 50:50 mixture, pumped at 1 ml/min, detection wavelength of 310 nm, column temperature of 30oC, and mobile phase as the diluent. Tepotinib (TPT), a fibroblast growth factor receptor inhibitor and anticancer medicine, has been approved by the FDA for use in the chemotherapy of urothelial carcinoma. HSA binding may affect the pharmacokinetics and pharmacodynamics of anticancer medicines. Tepotinib (TEPO), sotorasib (SOTO), and darolutamide (DARO) were tested as novel anticancer drugs utilizing a well-established, simple, rapid, and sensitive spectrofluorimetric approach. The spectrofluorimetric approach was based on the quantitative quenching of MER fluorescence at 538 nm after it had been activated at 350 nm with the prescribed drugs. Tepotinib, a highly selective MET inhibitor, was investigated in this Phase 1b/2 study in patients from the United States and Europe with advanced hepatocellular carcinoma (AHCC) who had previously received sorafenib treatment and showed MET overexpression.},
        keywords = {Tepotinib, Tyrosine, MET, Fibroblast, Urothelial Carcinoma, Sotorasib, Darolutamide.},
        month = {},
        }